Search - tctmd.com

Displaying 1 - 20 of 76

Sort: Relevancy | Date

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Todd Neale

October 22, 2025

News Conference News NY Valves 2025

Changes in Quality of Life Mirror TR Reductions After Tricuspid Procedures: Tri-QOL

Yael L. Maxwell

July 01, 2025

Presentation NY Valves 2025

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Presenter: Suzanne V. Arnold

June 25, 2025

News Daily News

Intermediate Disease May Be the ‘Sweet Spot’ for T-TEER Survival Benefit

Yael L. Maxwell

February 12, 2025

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

Presentation TCT 2024

Who to Treat With TTVI?

Presenter: Suzanne Arnold

October 30, 2024

Presentation TCT 2024

How to Interpret Patient Reported Outcomes (PROs): Lessons from the Regulatory Approval Trials in TTVI

Presenter: Suzanne Arnold

October 30, 2024

News Daily News

Slight Uptick in Mortality With TAVI in Recent Years: TVT Registry

Caitlin E. Cox

October 18, 2024

Presentation NY Valves 2024

Assessing Functional Status and Predicting Clinical Improvement

Presenter: Suzanne V. Arnold

June 07, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in VHD

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in TR Clinical Studies

Presenter: Suzanne V. Arnold

June 06, 2024

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

News Conference News TCT 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

Yael L. Maxwell

October 26, 2023

Presentation TCT 2023

The Importance of Patient Reported Outcomes in TR Trials

Presenter: Suzanne Arnold

October 26, 2023

Presentation TCT 2023

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

Presenter: Suzanne Arnold

October 26, 2023

Presentation TCT 2023

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

Presenter: Suzanne Arnold

October 25, 2023

Presentation TCT 2023

PROs are a Powerful Endpoint in TR Interventional Trials

Presenter: Suzanne Arnold

October 25, 2023

Advertisement

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Changes in Quality of Life Mirror TR Reductions After Tricuspid Procedures: Tri-QOL

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Intermediate Disease May Be the ‘Sweet Spot’ for T-TEER Survival Benefit

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Who to Treat With TTVI?

How to Interpret Patient Reported Outcomes (PROs): Lessons from the Regulatory Approval Trials in TTVI

Slight Uptick in Mortality With TAVI in Recent Years: TVT Registry

Assessing Functional Status and Predicting Clinical Improvement

The Importance of Patient Reported Outcomes in VHD

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

The Importance of Patient Reported Outcomes in TR Clinical Studies

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

The Importance of Patient Reported Outcomes in TR Trials

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

PROs are a Powerful Endpoint in TR Interventional Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content